Detalhe da pesquisa
1.
Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.
Leukemia
; 21(9): 1971-6, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17597804
2.
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.
Leukemia
; 20(6): 1028-34, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16617318
3.
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.
Leukemia
; 20(8): 1400-7, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16728981
4.
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Leukemia
; 31(11): 2398-2406, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28804124
5.
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability.
Leukemia
; 19(7): 1192-7, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15858613
6.
Induction of centrosome and chromosome aberrations by imatinib in vitro.
Leukemia
; 19(9): 1573-8, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15990860
7.
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
Leukemia
; 30(12): 2342-2350, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27416984
8.
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
Leukemia
; 30(1): 136-43, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26464169
9.
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
Leukemia
; 30(6): 1255-62, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26859076
10.
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Leukemia
; 29(5): 1115-22, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25567135
11.
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Leukemia
; 29(5): 1123-32, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25676422
12.
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.
Leukemia
; 28(7): 1478-85, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24472814
13.
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
Leukemia
; 28(10): 1988-92, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24798484
14.
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.
Leukemia
; 31(10): 2271-2273, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751768
15.
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Leukemia
; 26(9): 2096-102, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22446502
16.
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
Leukemia
; 27(11): 2254-6, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23615556